Renalytix Plc (LON:RENX – Get Free Report)’s share price traded down 1.6% during mid-day trading on Tuesday . The stock traded as low as GBX 1.80 and last traded at GBX 1.87. Approximately 194,919 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 834,957 shares. The stock had previously closed at GBX 1.90.
Renalytix Price Performance
The company has a quick ratio of 2.42, a current ratio of 1.21 and a debt-to-equity ratio of -118.57. The firm has a market cap of £8.17 million, a PE ratio of -0.47 and a beta of 1.81. The firm’s fifty day simple moving average is GBX 1.82 and its two-hundred day simple moving average is GBX 3.62.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Featured Articles
- Five stocks we like better than Renalytix
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
